-

Hyperfine, Inc. to Announce Second Quarter 2025 Financial Results on August 13, 2025

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.’s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call.

About the Swoop® Portable MRI Systems

The Swoop® Portable MR Imaging® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

About Hyperfine, Inc.

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit HyperfineMRI.com.

The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc.

Contacts

Investors
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com

Hyperfine, Inc.

NASDAQ:HYPR

Release Versions

Contacts

Investors
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com

Social Media Profiles
More News From Hyperfine, Inc.

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

GUILFORD, Conn.--(BUSINESS WIRE)--Peer-reviewed NEURO PMR results and 3,000+ office brain MRI scans support growing use of the Swoop system across neurology practices....

Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

GUILFORD, Conn.--(BUSINESS WIRE)--FDA-cleared Optive AI software enhances Swoop system image quality, clinical utility, ease of use, and isotropic imaging capability....

Hyperfine, Inc. Reports Second Quarter 2026 Financial Results

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2026 financial results and provided a business update. “Q2 was another strong quarter for Hyperfine, marked by solid growth in placements and revenue, continued gross margin expansion, disciplined operating expense...
Back to Newsroom